Compare Southwest Airlines Co (LUV) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southwest Airlines Co vs Spyre Therapeutics Inc. Common Stock — how do they compare? Southwest Airlines Co trades at $39.3 (market cap $19.89B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Southwest Airlines Co is far larger — about 2.6× Spyre Therapeutics Inc. Common Stock's market cap, and Southwest Airlines Co pays a 1.77% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Southwest Airlines Co for 66 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| LUV | SYRE | |
|---|---|---|
Market Cap | $19.89B | $7.52B |
Volume | 3,985,163 | 1,441,031 |
Sector | Industrials | Health |
52-Week High | $54.80 | $108.92 |
52-Week Low | $29.67 | $22.18 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $22.98B | $6.52B |
Dividend Yield | 1.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southwest Airlines (LUV) trades at $39.34, down 3.48% today, showing bearish technical signals with mixed earnings performance. The company reported a Q2 2026 EPS beat ($0.94 vs $0.51 expected) but missed Q1 expectations. Fundamentals show modest revenue growth to $28.06B in 2025 with a thin 2.78% net margin, though valuation appears reasonable with P/S of 0.71 and P/E of 25.41. Recent news highlights Southwest's commercial transformation initiatives targeting over $2B EBIT in 2026.
LUV presents a turnaround opportunity with analyst consensus target of $49.61 offering 26% upside, though near-term headwinds from high fuel costs and competitive pressures persist. The stock's bearish technical setup and volatile earnings history require careful risk management, but successful execution of revenue initiatives could drive significant shareholder value.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
